|
1
|
Brodeur GM: Neuroblastoma: biological
insights into a clinical enigma. Nat Rev Cancer. 3:203–216. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Furchert SE, Lanvers-Kaminsky C, Juurgens
H, Jung M, Loidl A and Frühwald MC: Inhibitors of histone
deacetylases as potential therapeutic tools for high-risk embryonal
tumors of the nervous system of childhood. Int J Cancer.
120:1787–1794. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mossman D and Scott RJ: Long term
transcriptional reactivation of epigenetically silenced genes in
colorectal cancer cells requires DNA hypomethylation and histone
acetylation. PloS One. 6:e231272011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Santini V, Gozzini A and Ferrari G:
Histone deacetylase inhibitors: molecular and biological activity
as a premise to clinical application. Curr Drug Metab. 8:383–393.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bokelmann I and Mahlknecht U: Valproic
acid sensitizes chronic lymphocytic leukemia cells to apoptosis and
restores the balance between pro- and antiapoptotic proteins. Mol
Med. 14:20–27. 2007.PubMed/NCBI
|
|
6
|
Fullgrabe J, Hajji N and Joseph B:
Cracking the death code: apoptosis-related histone modifications.
Cell Death Differ. 1:1238–1243. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hrebackova J, Poljakova J, Eckschlager T,
et al: Histone deacetylase inhibitors valproate and trichostatin A
are toxic to neuroblastoma cells and modulate cytochrome P450 1A1,
1B1 and 3A4 expression in these cells. Interdiscip Toxicol.
2:205–210. 2009. View Article : Google Scholar
|
|
8
|
Cinatl J, Scholz M, Driever PH, et al:
Antitumor activity of sodium valproate in cultures of human
neuroblastoma cells. Anticancer Drugs. 7:766–773. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Michaelis M, Suhan T and Cinatl J, Driever
PH and Cinatl J: Valproic acid and interferon-α synergistically
inhibit neuroblastoma cell growth in vitro and in
vivo. Int J Oncol. 25:1795–1799. 2004.
|
|
10
|
Harris AL: Hypoxia - a key regulatory
factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vaupel P, Kallinowski F and Okunieff P:
Blood flow, oxygen and nutrient supply, and metabolic
microenvironment of human tumors: a review. Cancer Res.
49:6449–6465. 1989.PubMed/NCBI
|
|
12
|
Hussein D, Estlin EJ, Dive C and Makin GW:
Chronic hypoxia promotes hypoxia-inducible factor-1alpha-dependent
resistance to etoposide and vincristine in neuroblastoma cells. Mol
Cancer Ther. 5:2241–2250. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lara PC, Lloret M, Clavo B, et al: Severe
hypoxia induces chemo-resistance in clinical cervical tumors
through MVP over-expression. Radiat Oncol. 4:292009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Song X, Liu X, Chi W, et al:
Hypoxia-induced resistance to cisplatin and doxorubicin in
non-small cell lung cancer is inhibited by silencing of HIF-1alpha
gene. Cancer Chemother Pharmacol. 58:776–784. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Giuntoli S, Rovida E, Barbetti V,
Cipolleschi MG, Olivotto M and Dello Sbarba P: Hypoxia suppresses
BCR/Abl and selects imatinib-insensitive progenitors within clonal
CML populations. Leukemia. 20:1291–1293. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang LE, Bindra RS, Glazer PM and Harris
AL: Hypoxia-induced genetic instability - a calculated mechanism
underlying tumor progression. J Mol Med (Berl). 85:139–148. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Brizel DM, Scully SP, Harrelson JM, et al:
Tumor oxygenation predicts for the likelihood of distant metastases
in human soft tissue sarcoma. Cancer Res. 56:941–943.
1996.PubMed/NCBI
|
|
18
|
Hockel M, Schlenger K, Aral B, et al:
Association between tumor hypoxia and malignant progression in
advanced cancer of the uterine cervix. Cancer Res. 56:4509–4515.
1996.PubMed/NCBI
|
|
19
|
Hockel M, Schlenger K, Hockel S and Vaupel
P: Hypoxic cervical cancers with low apoptotic index are highly
aggressive. Cancer Res. 59:4525–4528. 1999.PubMed/NCBI
|
|
20
|
Bossy-Wetzel E and Green DR: Detection of
apoptosis by annexin V labeling. Methods Enzymol. 322:15–18. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pfaffl MW, Horgan GW and Dempfle L:
Relative expression software tool (REST) for group-wise comparison
and statistical analysis of relative expression results in
real-time PCR. Nucleic Acids Res. 30:e362002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yin X-M: Bid, a BH3-only multi-functional
molecule, is at the cross road of life and death. Gene. 369:7–19.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Baek JH, Jang JE, Kang CM, Chung HY, Kim
ND and Kim KW: Hypoxia-induced VEGF enhances tumor survivability
via suppression of serum deprivation-induced apoptosis. Oncogene.
19:4621–4631. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu X-H, Yu EZ, Li Y-Y and Kagan E:
HIF-1alpha has an anti-apoptotic effect in human airway epithelium
that is mediated via Mcl-1 gene expression. J Cell Biochem.
97:755–765. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee J-W, Bae S-H, Jeong J-W, Kim S-H and
Kim K-W: Hypoxia-inducible factor (HIF-1)alpha: its protein
stability and biological functions. Exp Mol Med. 36:1–12. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Semenza GL: HIF-1: mediator of
physiological and pathophysiological responses to hypoxia. J Appl
Physiol. 88:1474–1480. 2000.PubMed/NCBI
|
|
27
|
Shannon AM, Bouchier-Hayes DJ, Condron CM
and Toomey D: Tumour hypoxia, chemotherapeutic resistance and
hypoxia-related therapies. Cancer Treat Rev. 29:297–307. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Um JH, Kang CHD, Bae JH, et al:
Association of DNA-dependent protein kinase with hypoxia inducible
factor-1 and its implication in resistance to anticancer drugs in
hypoxic tumor cells. Exp Mol Med. 36:233–242. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Graeber TG, Osmanian C, Jacks T, et al:
Hypoxia-mediated selection of cells with diminished apoptotic
potential in solid tumours. Nature. 379:88–91. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu L, Ning X, Sun L, et al:
Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced
chemoresistance in gastric cancer. Cancer Sci. 99:121–128.
2008.PubMed/NCBI
|
|
31
|
Piret J-P, Mottet D, Raes M and Michielis
C: Is HIF-1alpha a pro- or an anti-apoptotic protein? Biochem
Pharmacol. 64:889–892. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Suzuki H, Tomida a and Tsuruo T:
Dephosphorylated hypoxia-inducible factor 1alpha as a mediator of
p53-dependent apoptosis during hypoxia. Oncogene. 20:5779–5788.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim SH, Jeong JW, Park JA, et al:
Regulation of the HIF-1α stability by histone deacetylases. Oncol
Rep. 17:647–651. 2007.
|
|
34
|
An WG, Kanekal M, Simon MC, Maltepe E,
Blagosklonny MV and Neckers LM: Stabilization of wild-type p53 by
hypoxia-inducible factor 1alpha. Nature. 392:405–408. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sendoel A, Kohler I, Fellmann C, Lowe WS
and Hengartner OM: HIF-1 antagonizes p53-mediated apoptosis through
a secreted neuronal tyrosinase. Nature. 465:577–585. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nardinocchi L, Puca R and Orazi GD: HIF-1α
antagonizes p53-mediated apoptosis by triggering HIPK2 degradation.
Aging. 3:33–43. 2011.
|
|
37
|
Flamant L, Notte A, Ninane N, Raes M and
Michiels C: Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel
exposed breast cancer cells under hypoxia. Mol Cancer. 9:1912010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dong Z, Venkatachalam Ma, Wang J, et al:
Up-regulation of apoptosis inhibitory protein IAP-2 by hypoxia.
Hif-1-independent mechanisms. J Biol Chem. 276:18702–18709. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Piret J-P, Cosse J-P, Ninane N, Raes M and
Michiels C: Hypoxia protects HepG2 cells against etoposide-induced
apoptosis via a HIF-1-independent pathway. Exp Cell Res.
312:2908–2920. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen G, Yuan PX, Jiang YM, Huang LD and
Manji HK: Valproate robustly enhances AP-1 mediated gene
expression. Brain Res Mol Brain Res. 64:52–58. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hrebackova J, Hrabeta J and Eckschlager T:
Valproic acid in the complex therapy of malignant tumors. Curr Drug
Targets. 11:361–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Catalano MG, Fortunati N, Pugliese M, et
al: Valproic acid induces apoptosis and cell cycle arrest in poorly
differentiated thyroid cancer cells. J Clin Endocrinol Metab.
90:1383–1389. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nebbioso A, Clarke N, Voltz E, et al:
Tumor-selective action of HDAC inhibitors involves TRAIL induction
in acute myeloid leukemia cells. Nat Med. 11:77–84. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Muhlethaler-Mottet A, Meier R, Flahaut M,
et al: Complex molecular mechanisms cooperate to mediate histone
deacetylase inhibitors anti-tumour activity in neuroblastoma cells.
Mol Cancer. 7:552008. View Article : Google Scholar
|
